Display Settings:

Format

Send to:

Choose Destination
    Haematologica. 2011 Mar;96(3):454-8. Epub 2010 Nov 25.

    Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.

    Source

    Division of Hematology, Department of Hematology Oncology, University of Pavia Medical School and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

    Abstract

    Within a cohort of 1,915 consecutive patients with myeloproliferative neoplasm followed for a median time of 5.2 years (range 0-33.3), we investigated the occurrence of lymphoid neoplasm with the aim of defining this risk and to investigate the role of genetic predisposing factors. We identified 22 patients with myeloproliferative neoplasm who developed lymphoid neoplasm over their lifetime. We found that the risk of developing lymphoid neoplasm was 2.79-fold higher (95% CI, 1.80-4.33; P<0.001) than that of the general Italian population. A tag SNP surrogate for JAK2 GGCC haplotype was used to clarify a potential correlation between lymphoid-myeloid neoplasm occurrence and this genetic predisposing factor. As we did not find any difference in GGCC haplotype frequency between patients with both myeloid and lymphoid neoplasm and patients with myeloid neoplasm, JAK2 GGCC haplotype should not be considered a genetic predisposing factor. No difference in familial clustering was observed between the two groups.

    PMID:
    21109692
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3046278
    Free PMC Article

    Images from this publication.See all images (1) Free text

    Figure 1.

      Supplemental Content

      Icon for HighWire Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk